Exagen Inc. · NASDAQ:XGN

Exagen — Q3 2026 Earnings Presentation

30 slides from Exagen's earnings presentation, Nov 10, 2026

  1. Slide 1: Q3'26 Financial Results Webcast

    Q3’26 Financial Results Webcast John Aballi, President & CEO | Jeff Black, CFO November 10, 2026

  2. Slide 2: Disclaimer

    Disclaimer This presentation and all oral statements made by Exagen Inc.’s (“Exagen” or the “Company”) officers, directors or employees in connection with this presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve ris

  3. Slide 3: Q3 & YTD'26 Financial Highlights

    Q3 & YTD’26 $18.4M $451 Financial Q3 revenue; Best third quarter in history Q3 AVISE TTM ASP 14th consecutive Q of growth Highlights On track to deliver a record year >11% >30% Revenue growth YTD Adjusted EBITDA growth YTD

  4. Slide 4: Objectives to deliver long-term, profitable growth

    4 Objectives to deliver long-term, profitable growth 1 Expand adoption 2 Increase ASP 3 Innovate • Upgrade & expand sales force • Effective RCM & market • Invest in high-potential projects • Support science with evidence access strategies • Regular new product cadence • AI optimized processes • Eval

  5. Slide 5: Adoption is driving AVISE CTD volume growth

    5 1 EXPAND ADOPTION Adoption is driving AVISE CTD volume growth Total volume YTD (000s) 1.3M 110 +8% growth YoY YTD AVISE tests since launch 100 45 territories Productivity continues to improve, even with new territories ramping 90 2 of 9 80 Exagen abstracts selected for podium presentation at ACR C

  6. Slide 6: Process optimization fueling continued RCM progress

    6 2 INCREASE ASP Process optimization fueling continued RCM progress TTM $ASP* +$10 $460 $451 TTM ASP YoY $440 14th Consecutive quarter of YoY growth $420 $400 >2.5x $380 YoY growth in YTD claims recovered >12 months old 2024 2025 2026 6 | *As of Q3 in each year

  7. Slide 7: Positioning to advance Myositis testing

    7 3 INNOVATE Positioning to advance Myositis testing Launch of first new standalone product will leverage established channel >100K U.S. disease prevalence On track for early 2027 launch understates testing opportunity • Rare, but clinically severe autoimmune disease that can Clinical validation com

  8. Slide 8: Exagen Forward: Building the Autoimmune Platform

    8 SAVE THE DATE EXAGEN FORWARD Building the Autoimmune Platform December 15 | 12:00pm ET Livestream Further detail coming soon 8

  9. Slide 9: Revenue

    FINANCIAL RESULTS Revenue • Adoption and utilization drove Q3’25 Q3’26 YoY YTD’25 YTD’26 YoY volume growth despite seasonality • 6% growth in revenue per territory* Total Revenue $17.2M $18.4M 7% $49.9M $57.7M 11% • RCM contributed to ASP expansion with ~$800K collected on claims Test volume 2% 8% o

  10. Slide 10: Income Statement

    FINANCIAL RESULTS Income Statement • Gross margin improvement Q3’25 Q3’26 YoY YTD’25 YTD’26 YoY driven by ASP expansion, operating leverage and ongoing Gross margin % 58.4% 58.8% +40bps 59.3% 59.7% +50bps COGS rationalization Operating expenses $13.2M $15.2M +16% $38.7M $42.8M +11% • Q3 opex include

  11. Slide 11: Opportunistically strengthened balance sheet

    FINANCIAL RESULTS Opportunistically strengthened balance sheet Runway to fund business to sustainably positive AEBITDA and operating cash flow • Increased cash by $3.5M in Q3 • Added $6.5M in cash through ATM during Q3 $30M • Drew $5M from expiring $10M $75M tranche under debt facility after Availab

  12. Slide 12: FY 2026 Revenue Outlook

    FINANCIAL RESULTS FY 2026 Revenue Outlook Both volume and ASP contributing to growth $72M to $75M • 8% to 13% revenue growth YoY • Volume: High-single digit % growth • ASP: Mid-single digit % growth compared to Q4 2025 exit rate 12 | Guidance as of November 3, 2026

  13. Slide 13: Appendix

    EXAGE'N Appendix

  14. Slide 14: Identifying autoimmune disease is a challenge

    4 Identifying autoimmune disease is a challenge. Ambiguous symptoms Manifestations overlap Outdated technology Testing delays Tests lack specificity, sensitivity High rate of misdiagnosis 14

  15. Slide 15: Patients spend years seeking answers

    15 Patients spend years 6 LUPUS & SJÖGRENS seeking answers. years RHEUMATOID ARTHRITIS & MYOSITIS 15 doctor visits 58 lab procedures 2 years CANCER 4 to 6 months Exagen delivers clarity earlier. 15 | Sources on file. Graphics are not to scale.

  16. Slide 16: Earlier intervention improves outcomes

    16 THE PATIENT CHALLENGE Earlier intervention improves outcomes. Lupus Rheumatoid Arthritis 25% Reduction in lupus- related hospitalization1 within first 2 years Inflammation will lead to articular damage & bone erosion without treatment.3 1.5x Reduction in mortality risk related to irreversible org

  17. Slide 17: Conventional biomarkers aren't specific to one disease

    THE CLINICAL CHALLENGE Conventional Systemic sclerosis Rheumatoid biomarkers aren’t arthritis specific to one centromere dsDNA ACPA DNA-topoisomerase I histone Sm disease. RNA-topoisomerase III NOR90 nucleosome C1q Fc of IgG Th/To A single autoantibody can carry RNP ribosomal P SSa multiple clinical

  18. Slide 18: Lack of clarity leaves millions without answers

    THE CLINICAL CHALLENGE Lack of clarity leaves millions >41M Americans ANA+* without answers. ANA+: antinuclear antibody positive, first-line screen for autoimmune disease ≠ Diagnosed prevalence disease prevalence - between that gap, permanent damage happens Americans ~1.5M diagnosed with lupus* ~1M

  19. Slide 19: AVISE Testing: the simple, clear choice for clinicians

    OUR PROPRIETARY SOLUTION 2 tubes of AVISE Testing: patient’s blood the simple, clear choice for clinicians Rheumatologist Exagen lab >1.2M AVISE CTD tests completed Simple | Proven | Trusted AVISE CTD report • Comprehensive panel aids autoimmune disease diagnosis • Proprietary markers • Algorithmic

  20. Slide 20: AVISE outperforms conventional biomarkers

    OUR PROPRIETARY SOLUTION AVISE ® Test sensitivity for lupus outperforms 100% conventional 80% biomarkers 80% Conventional markers 66% 60% 44% Better diagnostic accuracy 40% 33% 20% 14% 0% anti-Smith anti-dsDNA C3/C4 CB-CAPs MAP Proprietary markers 20 1. Source: Putterman, et al., Lupus Science and M

  21. Slide 21: AVISE differentiation is earning adoption

    AVISE differentiation is earning adoption. Long-tailed opportunity to increase share in a growing market XGN2 Others >$2B 1 # biomarkers on one comprehensive panel 30 15 to 20 ~3% Leading combo of sensitivity & specificity* x U.S. autoimmune diagnostic testing Thresholds set for fewer false positive

  22. Slide 22: Leadership has deep diagnostics expertise

    22 Leadership has Chief Executive Officer Chief Financial Officer deep John Aballi Jeff Black diagnostics expertise. Medical & Lab Director Chief Scientific Officer Prashanti Reddy, MD Michael Mahler, PhD BOARD OF DIRECTORS Tina S. Nova PhD Bruce Robertson, PhD Frank Stokes Paul Kim Scott Kahn, PhD

  23. Slide 23: Robust, multi-cohort body of evidence

    23 1 ADVANCE ADOPTION Robust, multi-cohort body of evidence 15+ ~50K 3,500+ 12+ peer-reviewed publications patients studied in CAPSTONE clinically characterized subjects rheumatology practices Spanning 2012–2026 Real-world EHR + claims data Multi-center across U.S. In longitudinal utility studies An

  24. Slide 24: AVISE Lupus outperforms conventional biomarkers

    OUR SCIENCE AVISE Lupus outperforms conventional biomarkers 1 ® Demonstrated 80% sensitivity | 98% specificity against healthy individuals 100% Test sensitivity for lupus Receiver Operating Curve (ROC) 100% for SLE diagnosis1 80% Conventional markers 80% 66% 60% 60% 44% Sensitivity Sensitivity 40% 3

  25. Slide 25: AVISE CTD test result report

    25 OUR SCIENCE AVISE CTD test result report 1 ® Page 1 includes AVISE Lupus and additional SLE biomarkers Pages 2 and 3 contain a comprehensive antibody profile including novel including TC4d and autoantibodies to T Cells anti-RA33 and anti-PAD4 biomarkers Rheumatoid Arthritis Value Interpretation S

  26. Slide 26: Extensive, long-term I.P. protection

    OUR SCIENCE Extensive, Patent Families long-term • AVISE: cell-bound complement activation product for I.P. protection diagnosing SLE - 2032 • AVISE : treating & diagnosing likelihood of SLE - 2034 17 • Lupus nephritis biomarkers - 2045 • Use of T-cell autoantibodies + CB-CAPs in diagnosis of SLE -

  27. Slide 27: Demonstrated clinical benefits at scale

    EVIDENCE Demonstrated clinical benefits at scale Peer-reviewed Capstone Publication highlights improvements to patient care ~50,000 5.1× 2.8× $985 patient tests analyzed more likely to receive SLE Dx treatment-effect odds avg. annual lab-cost reduction AVISE+ vs. tANA+ (OR 5.11) New patients started

  28. Slide 28: Pipeline prioritizes innovation with impact

    3 INNOVATE Pipeline prioritizes innovation with impact Discover Assay developed Algorithmic Clinical validity Reimbursement Commercialized markers to CLIA standards discovery* & utility AVISE CTD expansions: RA33, T-Cell, PAD4 Myositis RA disease activity Lupus Nephritis (urine) Lupus Nephritis (blo

  29. Slide 29: Adjusted EBITDA Reconciliation

    Adjusted EBITDA Reconciliation Three Months Ended Nine Months Ended September 30, September 30, 2026 2025 2026 2025 (in thousands) Adjusted EBITDA Net loss $(6,336) $(7,087) $(13,499) $(15,278) Other (income) expense (181) (3) (202) (246) Interest expense 1,201 1,319 3,669 2,988 Loss on extinguishme

  30. Slide 30: Sources

    30 Sources Slide # 1. ANA+ prevalence (>41M) Dinse GE, Parks CG, Weinberg CR, et al. Increasing Prevalence 5. Other AVISE CTD autoimmune indications (~1M) of Antinuclear Antibodies in the United States. Arthritis Rheumatol. 2022;74(12):2032–2041. Psoriatic arthritis — CDC. Distribution of Arthritis

Exagen — Q3 2026 Earnings Presentation on 6ix